DexCom, Inc. (NASDAQ:DXCM) has shown a modest gain of 1.16% over the past 30 days, indicating positive investor sentiment.The company's projected growth potential of 22.52% underscores its promising future in the medical device industry.With a Piotroski Score of 8, DexCom demonstrates strong financial health, making it an attractive option for long-term investors.DexCom, Inc. (NASDAQ:DXCM) is a prominent player in the medical device industry, specializing in continuous glucose monitoring (CGM) systems for d ...

Key Takeaways DXCM beat Q4 EPS estimates as revenues rose 13% to $1.26B on strong U.S. and international demand.The nationwide G7 15 Day launch aims to set a new standard for customer experience.DXCM reaffirmed the 2026 revenue view of $5.16-$5.25B, projecting 11-13% growth.DexCom, Inc. (DXCM) reported fourth-quarter 2025 adjusted earnings per share (EPS) of 68 cents, which beat the Zacks Consensus Estimate of 65 cents by 4.6%. The company reported adjusted earnings of 45 cents per share in the prior-year q ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

DexCom (DXCM) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.62%. A quarter ago, it was expected that this medical device company would post earnings of $0.57 per share when it actually produced earnings of $0.61, delivering a surprise of +7.02%.Over the last four quarters, the co ...

Here's a look at the details in the report. Watch the price DXCM action here.The Details: DexCom reported quarterly earnings of 68 cents per share, which beat the Street estimate of 65 cents, according to data from Benzinga Pro.Quarterly revenue came in at $1.26 billion, which beat the analyst estimate of $1.25 billion.U.S. revenue grew 11% and international revenue grew 18% on a reported basis, all on a year-over-year basis.Outlook: DexCom affirmed its fiscal 2026 revenue outlook for a range of $5.16 billi ...

Dexcom (NasdaqGS:DXCM) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsDavid Roman - Managing DirectorJake Leach - President and CEOJereme Sylvain - CFOJoanne Wuensch - Managing DirectorJosh Jennings - Managing DirectorMarie Thibault - Managing DirectorMatt Taylor - Managing DirectorRichard Newitter - Managing DirectorSean Christensen - VP of Finance and Investor RelationsTravis Steed - Managing DirectorZachary Day - Equity Research AssociateConference Call ParticipantsBrandon Vazque ...

Dexcom (NasdaqGS:DXCM) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Company ParticipantsDavid Roman - Managing DirectorJake Leach - President and CEOJereme Sylvain - CFOJoanne Wuensch - Managing DirectorJosh Jennings - Managing DirectorMarie Thibault - Managing DirectorMatt Taylor - Managing DirectorRichard Newitter - Managing DirectorSean Christensen - VP of Finance and Investor RelationsTravis Steed - Managing DirectorZachary Day - Equity Research AssociateConference Call ParticipantsBrandon Vazque ...

Dexcom (NasdaqGS:DXCM) Q4 2025 Earnings call February 12, 2026 04:30 PM ET Speaker14Ladies and gentlemen, good afternoon, and welcome to the Dexcom fourth quarter and fiscal year 2025 earnings release conference call. My name is Abby, and I will be your operator today. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session. During the question-and-answer session, if you have a question, please press star one on your touchtone phone. As a reminder, the ...

Financial Performance - Fiscal 2025 revenue reached $4.66 billion, a 16% increase from 2024[454] - Gross profit for fiscal 2025 was $2.80 billion, up 15% from the previous year[454] - Operating income increased by 52% to $911.8 million in fiscal 2025[454] - Net income rose to $836.3 million, reflecting a 45% growth compared to 2024[454] - Operating cash flow for fiscal 2025 was $1.44 billion, up 46% from 2024[454] - Revenue from distributor sales in the U.S. was $3.20 billion, while international distributor sales totaled $763.3 million[466] - Revenue increased due to the addition of approximately 600,000 - 700,000 net customers, excluding Stelo customers, in 2025[468] Research and Development - Research and development expenses for fiscal 2025 were $599.1 million, an 8% increase from 2024[456] - Research and development expenses rose by $37.3 million primarily due to higher compensation costs, emphasizing the importance of R&D for future growth[470] Cash and Liquidity - The company ended fiscal 2025 with cash, cash equivalents, and short-term marketable securities totaling $2.00 billion[454] - Cash flows from operating activities were $1.44 billion for the twelve months ended December 31, 2025, an increase of $451.2 million compared to 2024[490] - Cash, cash equivalents, and short-term marketable securities totaled $2.00 billion as of December 31, 2025, a decrease of $580.7 million from the previous year[489] - The company expects to continue generating positive cash flows from operations for the foreseeable future[476] - As of December 31, 2025, the company had a working capital ratio of 1.88 and a quick ratio of 1.50, indicating sufficient current assets to cover short-term liabilities[480] - The company received net proceeds of $1.23 billion from the 2028 Notes offering, with plans to use the funds for general corporate purposes and capital expenditures[477] Debt and Financial Ratios - The debt-to-assets ratio was 0.20 as of December 31, 2025, indicating that total assets are sufficient to cover debts[482] Foreign Currency Exposure - A substantial portion of operations is in the U.S., with most sales made in U.S. dollars, leading to significant exposure to foreign currency fluctuations primarily affecting revenue[496] - Expansion of manufacturing sites in Ireland and Malaysia introduces additional foreign exchange currency risk, potentially impacting financial results[497] - Financial statements of international subsidiaries are translated into U.S. dollars using end-of-period exchange rates for assets and liabilities, affecting net income only upon sale or liquidation[498] - The company enters into foreign currency forward contracts to hedge monetary assets and liabilities, with derivative gains and losses included in other income[499] - Notional principal amounts of foreign currency contracts provide a measure of transaction volume but do not represent exposure to market loss[500] - The company actively monitors and manages financial exposures due to exchange rate fluctuations as part of its overall risk management program[500] Product Development - The company launched the G7 continuous glucose monitoring system in 2023 and plans to introduce the G7 15 Day system in late 2025[438] - Dexcom's Stelo biosensor for prediabetes and Type 2 diabetes was launched in August 2024, marking its entry into the over-the-counter market[438] Operating Expenses - Selling, general and administrative expenses increased by $83.7 million, offset by a $87.2 million decrease in legal expenses related to a settled lawsuit[470] - Gross profit margin percentage decreased in 2025 compared to 2024 due to supply availability inefficiencies and lower production yield[468]

Dexcom earnings Q4 2025 Safe harbor statement This presentation contains "forward - looking statements" that are based on our management's beliefs and assumptions and on inform ation available to management as of February 12, 2026. We intend for such forward - looking statements to be covered by the safe harbor provisions fo r forward - looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995. Forward - looking statements include informatio n concerning our possible or assum ...